IIB 

108TH CONGRESS 

2D SESSION H. R. 3866

IN THE SENATE OF THE UNITED STATES 

JUNE 3, 2004

Received; read twice and referred to the Committee on the Judiciary 

AN ACT

To amend the Controlled Substances Act to provide increased 

penalties for anabolic steroid offenses near sports facilities, and for other purposes.

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled,
2

HR 3866 RFS 

1 SECTION 1. SHORT TITLE. 

2 This Act may be cited as the ‘‘Anabolic Steroid Con3 trol Act of 2004’’. 

4 SEC. 2. INCREASED PENALTIES FOR ANABOLIC STEROID 

5 OFFENSES NEAR SPORTS FACILITIES. 

6 (a) IN GENERAL.—Part D of the Controlled Sub7 stances Act is amended by adding at the end the following: 

8 ANABOLIC STEROID OFFENSES NEAR SPORTS FACILITIES

9 ‘‘SEC. 424. (a) Whoever violates section 401(a)(1) or 

10 section 416 by manufacturing, distributing, or possessing 

11 with intent to distribute, an anabolic steroid near or at 

12 a sports facility is subject to twice the maximum term of 

13 imprisonment, maximum fine, and maximum term of su14 pervised release otherwise provided by section 401 for that 

15 offense. 

16 ‘‘(b) As used in this section—

17 ‘‘(1) the term ‘sports facility’ means real prop18 erty where athletic sports or athletic training takes 

19 place, if such property is privately owned for com20 mercial purposes or if such property is publicly 

21 owned, but does not include any real property de22 scribed in section 419; 

23 ‘‘(2) the term ‘near or at’ means in or on, or 

24 within 1000 feet of; and 
3

HR 3866 RFS 

1 ‘‘(3) the term ‘possessing with intent to dis2 tribute’ means possessing with the intent to dis3 tribute near or at a sports facility.’’. 

4 (b) TABLE OF CONTENTS AMENDMENT.—The table 

5 of contents for Comprehensive Drug Abuse Prevention 

6 and Control Act of 1970 is amended by inserting after 

7 the item relating to section 423 the following new item:

‘‘Sec. 424. Anabolic steroid offenses near sports facilities.’’.

8 SEC. 3. SENTENCING COMMISSION GUIDELINES. 

9 The United States Sentencing Commission shall—

10 (1) review the Federal sentencing guidelines 

11 with respect to offenses involving anabolic steroids; 

12 (2) consider amending the Federal sentencing 

13 guidelines to provide for increased penalties with re14 spect to offenses involving anabolic steroids in a 

15 manner that reflects the seriousness of such offenses 

16 and the need to deter anabolic steroid use; and 

17 (3) take such other action that the Commission 

18 considers necessary to carry out this section. 

19 SEC. 4. AMENDMENTS TO THE CONTROLLED SUBSTANCES 

20 ACT. 

21 (a) DEFINITIONS.—Section 102 of the Controlled 

22 Substances Act (21 U.S.C. 802) is amended—

23 (1) in paragraph (41)—

24 (A) by realigning the margin so as to align 

25 with paragraph (40); and 
4

HR 3866 RFS 

1 (B) by striking subparagraph (A) and in2 serting the following: 

3 ‘‘(A) The term ‘anabolic steroid’ means any drug or 

4 hormonal substance, chemically and pharmacologically re5 lated to testosterone (other than estrogens, progestins, 

6 corticosteroids, and dehydroepiandrosterone), and in7 cludes—

8 ‘‘(i) androstanediol—

9 ‘‘(I) 3β,17β-dihydroxy-5α-androstane; and 

10 ‘‘(II) 3α,17β-dihydroxy-5α-androstane; 

11 ‘‘(ii) androstanedione (5α-androstan-3,17-

12 dione); 

13 ‘‘(iii) androstenediol—

14 ‘‘(I) 1-androstenediol (3β,17β-dihydroxy15 5α-androst-1-ene); 

16 ‘‘(II) 1-androstenediol (3α,17β-dihydroxy17 5α-androst-1-ene); 

18 ‘‘(III) 4-androstenediol (3β,17β-dihydroxy19 androst-4-ene); and 

20 ‘‘(IV) 5-androstenediol (3β,17β-dihydroxy21 androst-5-ene); 

22 ‘‘(iv) androstenedione—

23 ‘‘(I) 1-androstenedione ([5α]-androst-1-en24 3,17-dione); 
5

HR 3866 RFS 

1 ‘‘(II) 4-androstenedione (androst-4-en2 3,17-dione); and 

3 ‘‘(III) 5-androstenedione (androst-5-en4 3,17-dione);

5 ‘‘(v) bolasterone (7α,17α-dimethyl-17β6 hydroxyandrost-4-en-3-one); 

7 ‘‘(vi) boldenone (17β-hydroxyandrost-1,4,-diene8 3-one); 

9 ‘‘(vii) calusterone (7β,17α-dimethyl-17β10 hydroxyandrost-4-en-3-one); 

11 ‘‘(viii) clostebol (4-chloro-17β-hydroxyandrost-4-

12 en-3-one); 

13 ‘‘(ix) dehydrochlormethyltestosterone (4-chloro14 17β-hydroxy-17α-methylandrost-1,4-dien-3-one); 

15 ‘‘(x) ∆1-dihydrotestosterone (also known as 1-

16 testosterone) (17β-hydroxy-5α-androst-1-en-3-one); 

17 ‘‘(xi) 4-dihydrotestosterone (17β-hydroxy18 androstan-3-one); 

19 ‘‘(xii) drostanolone (17β-hydroxy-2α-methyl-5α20 androstan-3-one); 

21 ‘‘(xiii) ethylestrenol (17α-ethyl-17β-hydroxyestr22 4-ene); 

23 ‘‘(xiv) fluoxymesterone (9-fluoro-17α-methyl24 11β,17β-dihydroxyandrost-4-en-3-one); 
6

HR 3866 RFS 

1 ‘‘(xv) formebolone (2-formyl-17α-methyl2 11α,17β-dihydroxyandrost-1,4-dien-3-one); 

3 ‘‘(xvi) furazabol (17α-methyl-17β4 hydroxyandrostano[2,3-c]-furazan); 

5 ‘‘(xvii) 13α-ethyl-17β-hydroxygon-4-en-3-one; 

6 ‘‘(xviii) 4-hydroxytestosterone (4,17β-dihydroxy7 androst-4-en-3-one); 

8 ‘‘(xix) 4-hydroxy-19-nortestosterone (4,17β9 dihydroxy-estr-4-en-3-one); 

10 ‘‘(xx) mestanolone (17α-methyl-17β-hydroxy11 5α-androstan-3-one); 

12 ‘‘(xxi) mesterolone (1α-methyl-17β-hydroxy13 [5α]-androstan-3-one); 

14 ‘‘(xxii) methandienone (17α-methyl-17β15 hydroxyandrost-1,4-dien-3-one); 

16 ‘‘(xxiii) methandriol (17α-methyl-3β,17β17 dihydroxyandrost-5-ene); 

18 ‘‘(xxiv) methenolone (1-methyl-17β-hydroxy-5α19 androst-1-en-3-one); 

20 ‘‘(xxv) methyltestosterone (17α-methyl-17β21 hydroxyandrost-4-en-3-one); 

22 ‘‘(xxvi) mibolerone (7α,17α-dimethyl-17β23 hydroxyestr-4-en-3-one); 
7

HR 3866 RFS 

1 ‘‘(xxvii) 17α-methyl-∆1-dihydrotestosterone (17 

2 β-hydroxy-17α-methyl-5α-androst-1-en-3-one) (also 

3 known as ‘17-α-methyl-1-testosterone’); 

4 ‘‘(xxviii) nandrolone (17β-hydroxyestr-4-en-3-

5 one); 

6 ‘‘(xxix) norandrostenediol—

7 ‘‘(I) 19-nor-4-androstenediol (3β, 17β8 dihydroxyestr-4-ene); 

9 ‘‘(II) 19-nor-4-androstenediol (3α, 17β10 dihydroxyestr-4-ene); 

11 ‘‘(III) 19-nor-5-androstenediol (3β, 17β12 dihydroxyestr-5-ene); and 

13 ‘‘(IV) 19-nor-5-androstenediol (3α, 17β14 dihydroxyestr-5-ene); 

15 ‘‘(xxx) norandrostenedione—

16 ‘‘(I) 19-nor-4-androstenedione (estr-4-en17 3,17-dione); and 

18 ‘‘(II) 19-nor-5-androstenedione (estr-5-en19 3,17-dione); 

20 ‘‘(xxxi) norbolethone (13β,17α-diethyl-17β21 hydroxygon-4-en-3-one); 

22 ‘‘(xxxii) norclostebol (4-chloro-17β-hydroxyestr23 4-en-3-one); 

24 ‘‘(xxxiii) norethandrolone (17α-ethyl-17β25 hydroxyestr-4-en-3-one); 
8

HR 3866 RFS 

1 ‘‘(xxxiv) oxandrolone (17α-methyl-17β-hydroxy2 2-oxa-[5α]-androstan-3-one);

3 ‘‘(xxxv) oxymesterone (17α-methyl-4,17β4 dihydroxyandrost-4-en-3-one); 

5 ‘‘(xxxvi) oxymetholone (17α-methyl-2-

6 hydroxymethylene-17β-hydroxy-[5α]-androstan-3-

7 one); 

8 ‘‘(xxxvii) stanozolol (17α-methyl-17β-hydroxy9 [5α]-androst-2-eno[3,2-c]-pyrazole); 

10 ‘‘(xxxviii) stenbolone (17β-hydroxy-2-methyl11 [5α]-androst-1-en-3-one); 

12 ‘‘(xxxix) testolactone (13-hydroxy-3-oxo-13,17-

13 secoandrosta-1,4-dien-17-oic acid lactone); 

14 ‘‘(xl) testosterone (17β-hydroxyandrost-4-en-3-

15 one); 

16 ‘‘(xli) tetrahydrogestrinone (13β,17α-diethyl17 17β-hydroxygon-4,9,11-trien-3-one); 

18 ‘‘(xlii) trenbolone (17β-hydroxyestr-4,9,11-trien19 3-one); and 

20 ‘‘(xliii) any salt, ester, or ether of a drug or 

21 substance described in this paragraph;’’; and 

22 (2) in paragraph (44), by inserting ‘‘anabolic 

23 steroids,’’ after ‘‘marihuana,’’. 
9

HR 3866 RFS 

1 (b) AUTHORITY AND CRITERIA FOR CLASSIFICA2 TION.—Section 201(g) of the Controlled Substances Act 

3 (21 U.S.C. 811(g)) is amended—

4 (1) in paragraph (1), by striking ‘‘substance 

5 from a schedule if such substance’’ and inserting 

6 ‘‘drug which contains a controlled substance from 

7 the application of titles II and III of the Comprehen8 sive Drug Abuse Prevention and Control Act (21 

9 U.S.C. 802 et seq.) if such drug’’; and 

10 (2) in paragraph (3), by adding at the end the 

11 following: 

12 ‘‘(C) Upon the recommendation of the Sec13 retary of Health and Human Services, a compound, 

14 mixture, or preparation which contains any anabolic 

15 steroid, which is intended for administration to a 

16 human being or an animal, and which, because of its 

17 concentration, preparation, formulation or delivery 

18 system, does not present any significant potential for 

19 abuse.’’. 

20 (c) ANABOLIC STEROIDS CONTROL ACT.—Section 

21 1903 of the Anabolic Steroids Control Act of 1990 (Public 

22 Law 101–647; 21 U.S.C. 802 note) is amended—

23 (1) by striking subsection (a); and 

24 (2) by redesignating subsections (b) and (c) as 

25 subsections (a) and (b), respectively. 
10

HR 3866 RFS 

1 SEC. 5. REPORTING REQUIREMENT. 

2 Not later than 2 years after the date of the enact3 ment of this Act, the Secretary of Health and Human 

4 Services, in consultation with the Attorney General, shall 

5 prepare and submit a report to the Judiciary Committee 

6 of the House and Senate, and to the Committee on Energy 

7 and Commerce of the House, evaluating the health risks 

8 associated with dietary supplements not scheduled under 

9 the amendments made by this Act which contain sub10 stances similar to those added to the list of controlled sub11 stances under those amendments. The report shall include 

12 recommendations on whether such substances should be 

13 regulated as anabolic steroids.

Passed the House of Representatives June 3, 2004. 

Attest: JEFF TRANDAHL, 

Clerk.